Oxcarbazepine Tablet, Film Coated
Product Images NDC 72603-272

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 72603-272). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepinetablets300mg100s (Oxcarbazepinetablets300mg100s)

Label for Oxcarbazepine Tablets, USP 300 mg film-coated tablets, oral use. The label indicates 100 tablets per container and includes storage instructions, manufacturer and labeler information (Northstar Rx LLC and Annora Pharma Pvt. Ltd., India), and pharmacy dispensing guidance. Features a barcode and batch coding area on a blue and white background.*

FDA Label Image

Oxcarbazepinetablets600mg100s (Oxcarbazepinetablets600mg100s)

Packaging label for Oxcarbazepine Tablets, USP 600 mg film-coated tablets. The label indicates the product contains 100 tablets and is manufactured for NorthStar Rx LLC. It includes storage instructions, pharmacy dispensing guidance, a barcode, and manufacturing details for Annora Pharma Pvt. Ltd., India.*

FDA Label Image

Oxcarbazepinetabletsfigure1 (Oxcarbazepinetabletsfigure1)

A Kaplan-Meier survival curve chart comparing exit rates over time from Day 2 to Day 11 between two treatment groups: Oxcarbazepine (solid line) and Placebo (dotted line). The y-axis represents exit rate from 0.0 to 1.0, and the x-axis represents time on trial in days. The chart includes a log-rank test p-value of 0.0001.*

FDA Label Image

Oxcarbazepinetabletsfigure2 (Oxcarbazepinetabletsfigure2)

A Kaplan-Meier curve graph showing seizure rate over time in days from first dose to first seizure. The graph compares two treatment groups: Oxcarbazepine (solid line) and Placebo (dashed line), with the Oxcarbazepine group exhibiting a lower seizure rate over the 140-day period. A log-rank test p-value of 0.046 is noted on the graph.*

FDA Label Image

Oxcarbazepinetabletsfigure3 (Oxcarbazepinetabletsfigure3)

A Kaplan-Meier survival curve chart showing exit rate over time in days, comparing two treatment groups labeled High and Low. The High group is represented by a solid line, and the Low group by a dashed line. The chart includes a log-rank test p-value of 0.0001, indicating statistical comparison between groups.*

FDA Label Image

Oxcarbazepinetabletsfigure4 (Oxcarbazepinetabletsfigure4)

A Kaplan-Meier survival plot showing exit rate over time in days for two treatment groups labeled 'High' and 'Low'. The exit rate is plotted on the vertical axis, and time to exit in days on the horizontal axis, with the low treatment group showing a higher exit rate earlier than the high treatment group, supported by a log-rank test p-value of 0.0001.*

FDA Label Image

Oxcarbazepinetabletsstructure (Oxcarbazepinetabletsstructure)

Chemical structure of oxcarbazepine, depicting molecular bonds and atomic arrangement, including carbon, nitrogen, oxygen atoms, and functional groups characteristic of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.